-
公开(公告)号：US12202910B2
公开(公告)日：2025-01-21
申请号：US17849467
申请日：2022-06-24
Applicant: PFIZER INC.
Inventor： Danielle Elizabeth Dettling , Yik Andy Yeung , Kristian Todd Poulsen , Veena Krishnamoorthy , Cesar Adolfo Sommer
Abstract: The present invention provides antibodies that specifically bind to FLT3 (Fms-Like Tyrosine Kinase 3). The invention further provides bispecific antibodies that bind to FLT3 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of FLT3-mediated pathologies, including cancer such as Acute Myeloid Leukemia (AML).
-
公开(公告)号：US11059876B2
公开(公告)日：2021-07-13
申请号：US16286158
申请日：2019-02-26
Applicant: Pfizer Inc.
Inventor： Yik Andy Yeung , Reid Martin Renny Feldman , Ling Hon Matthew Chu , Javier Fernando Chaparro Riggers , Ivana Djuretic , Laura Lin , Lidia Mosyak
IPC: C07K14/54 , A61K39/395 , A61K38/17 , A61K38/20 , A61K35/17 , C07K19/00 , A61P35/00 , C07K16/32 , C07K16/28 , C07K14/55 , C12N15/62 , A61K38/19 , A61K45/06
Abstract: The present invention relates to human interleukin 15 (IL-15) variants that have therapeutic and diagnostic use, and methods for making thereof. The present invention also provides fusion proteins comprising a human IL-15 variant. Also provided are methods of stimulating or suppressing immune responses in a mammal, and methods of treating a disorder (e.g., cancer) using the IL-15 variants or the fusion protein of such IL-15 variants.
-
公开(公告)号：US09969809B2
公开(公告)日：2018-05-15
申请号：US15085644
申请日：2016-03-30
Applicant: PFIZER INC.
Inventor： Tracy Chia-Chien Kuo , Javier Fernando Chaparro Riggers , Wei Chen , Amy Shaw-Ru Chen , Edward Derrick Pascua , Thomas John Van Blarcom , Leila Marie Boustany , Weihsien Ho , Yik Andy Yeung , Pavel Strop , Arvind Rajpal
IPC: C07K16/00 , C07K16/28 , A61K39/395 , A61K31/454 , A61K31/704 , A61K47/48 , A61K31/69 , A61K39/00
CPC classification number: C07K16/2878 , A61K31/454 , A61K31/69 , A61K31/704 , A61K39/3955 , A61K39/39558 , A61K47/6801 , A61K47/6849 , A61K2039/505 , C07K16/2803 , C07K16/2809 , C07K2317/21 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/92 , A61K2300/00
Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.
-
公开(公告)号：US20210324028A1
公开(公告)日：2021-10-21
申请号：US17356754
申请日：2021-06-24
Applicant: Pfizer Inc.
Inventor： Yik Andy Yeung , Reid Martin Renny Feldman , Ling Hon Matthew Chu , Javier Fernando Chaparro Riggers , Ivana Djuretic , Laura Lin , Lidia Mosyak
IPC: C07K14/54 , A61K35/17 , C07K19/00 , A61P35/00 , A61K38/17 , C07K16/32 , C07K16/28 , C07K14/55 , C12N15/62 , A61K38/19 , A61K39/395 , A61K38/20
Abstract: The present invention relates to human interleukin 15 (IL-15) variants that have therapeutic and diagnostic use, and methods for making thereof. The present invention also provides fusion proteins comprising a human IL-15 variant. Also provided are methods of stimulating or suppressing immune responses in a mammal, and methods of treating a disorder (e.g., cancer) using the IL-15 variants or the fusion protein of such IL-15 variants.
-
公开(公告)号：US10793635B2
公开(公告)日：2020-10-06
申请号：US16017974
申请日：2018-06-25
Applicant: PFIZER INC.
Inventor： Tracy Chia-Chien Kuo , Javier Fernando Chaparro Riggers , Wei Chen , Amy Shaw-Ru Chen , Edward Derrick Pascua , Thomas John Van Blarcom , Leila Marie Boustany , Weihsien Ho , Yik Andy Yeung , Pavel Strop , Arvind Rajpal
IPC: A61K39/395 , C07K16/28 , A61K31/454 , A61K31/704 , A61K31/69 , A61K47/68 , A61K39/00
Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.
-
Patent Agency Ranking
公开(公告)号：US11814435B2
公开(公告)日：2023-11-14
申请号：US17005073
申请日：2020-08-27
Applicant: PFIZER INC.
Inventor： Tracy Chia-Chien Kuo , Javier Fernando Chaparro Riggers , Wei Chen , Amy Shaw-Ru Chen , Edward Derrick Pascua , Thomas John Van Blarcom , Leila Marie Boustany , Weihsien Ho , Yik Andy Yeung , Pavel Strop , Arvind Rajpal
IPC: C07K16/00 , C07K16/28 , A61K39/395 , A61K31/454 , A61K31/704 , A61K31/69 , A61K47/68 , A61K39/00
CPC classification number: C07K16/2878 , A61K31/454 , A61K31/69 , A61K31/704 , A61K39/3955 , A61K39/39558 , A61K47/6801 , A61K47/6849 , C07K16/2803 , C07K16/2809 , A61K2039/505 , C07K2317/21 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/92 , A61K31/69 , A61K2300/00 , A61K31/704 , A61K2300/00 , A61K31/454 , A61K2300/00
Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.
-
公开(公告)号：US11421040B2
公开(公告)日：2022-08-23
申请号：US15993874
申请日：2018-05-31
Applicant: PFIZER INC.
Inventor： Danielle Elizabeth Dettling , Yik Andy Yeung , Kristian Todd Poulsen , Veena Krishnamoorthy , Cesar Adolfo Sommer
Abstract: The present invention provides antibodies that specifically bind to FLT3 (Fms-Like Tyrosine Kinase 3). The invention further provides bispecific antibodies that bind to FLT3 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of FLT3-mediated pathologies, including cancer such as Acute Myeloid Leukemia (AML).
-
公开(公告)号：US20190263877A1
公开(公告)日：2019-08-29
申请号：US16286158
申请日：2019-02-26
Applicant: Pfizer Inc.
Inventor： Yik Andy Yeung , Reid Martin Renny Feldman , Ling Hon Matthew Chu , Javier Fernando Chaparro Riggers , Ivana Djuretic , Laura Lin , Lidia Mosyak
IPC: C07K14/54 , C07K14/55 , A61K35/17 , C07K19/00 , A61P35/00 , A61K38/17 , C07K16/32 , C07K16/28 , C12N15/62
Abstract: The present invention relates to human interleukin 15 (IL-15) variants that have therapeutic and diagnostic use, and methods for making thereof. The present invention also provides fusion proteins comprising a human IL-15 variant. Also provided are methods of stimulating or suppressing immune responses in a mammal, and methods of treating a disorder (e.g., cancer) using the IL-15 variants or the fusion protein of such IL-15 variants.
-
公开(公告)号：US11155630B2
公开(公告)日：2021-10-26
申请号：US17129833
申请日：2020-12-21
Applicant: PFIZER INC.
Inventor： Tracy Chia-Chien Kuo , Javier Fernando Chaparro Riggers , Wei Chen , Amy Shaw-Ru Chen , Edward Derrick Pascua , Thomas John Van Blarcom , Leila Marie Boustany , Weihsien Ho , Yik Andy Yeung , Pavel Strop , Arvind Rajpal
IPC: C07K16/28 , C07K16/30 , A61K39/395 , A61K31/454 , A61K31/704 , A61K31/69 , A61K47/68 , A61K39/00
Abstract: The present invention relates to bispecific antibodies that specific bind to BCMA (B-Cell Maturation Antigen) and CD3 (Cluster of Differentiation 3). Method of making the bispecific antibodies and method of using the bispecific antibodies for the treatment of multiple myeloma are also provided.
-
公开(公告)号：US10040860B2
公开(公告)日：2018-08-07
申请号：US15878344
申请日：2018-01-23
Applicant: PFIZER INC.
Inventor： Tracy Chia-Chien Kuo , Javier Fernando Chaparro Riggers , Wei Chen , Amy Shaw-Ru Chen , Edward Derrick Pascua , Thomas John Van Blarcom , Leila Marie Boustany , Weihsien Ho , Yik Andy Yeung , Pavel Strop , Arvind Rajpal
IPC: C07K16/00 , C07K16/28 , A61K39/395 , A61K31/454 , A61K47/68 , A61K31/69 , A61K31/704 , A61K39/00
CPC classification number: C07K16/2878 , A61K31/454 , A61K31/69 , A61K31/704 , A61K39/3955 , A61K39/39558 , A61K47/6801 , A61K47/6849 , A61K2039/505 , C07K16/2803 , C07K16/2809 , C07K2317/21 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/92 , A61K2300/00
Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.018 seconds)
